ClinicalTrials.gg
CompletedNCT01709513Updated Jun 23, 2020Results posted

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

A Phase 3 interventional study of Atorvastatin and Ezetimibe in Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Completed at 70 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-23.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
314
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
14th of 43
314 · median 107
Started
2012
with 11 others
Phase 3
20 of 43
none open now
Registered
18th of 43
by date
Lead sponsor
11 of 43
Regeneron Pharmaceuticals

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 14th largest by enrollment, is one of 12 that started in 2012, is one of 20 in phase 3, and was the 18th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

This is a randomized, double-blind, double-dummy, active-controlled, parallel-group, multi-national, multi-center study to compare alirocumab (REGN727/SAR236553) versus ezetimibe in participants with primary hypercholesterolemia and moderate, high, or very high CV risk, who are intolerant to statins. An atorvastatin arm is added to determine that the population selected in the study is a truly statin intolerant population by assessing skeletal muscle-related adverse events.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with primary hypercholesterolemia [Heterozygous Familial Hypercholesterolemia (heFH) or non-FH] with moderate, high or very high CV risk and a history of statin intolerance
  2. Provide signed

Exclusion criteria

Exclusion:

  1. Calculated serum LDL-C \<70 mg/dL (1.81 mmol/L) and very high CV risk at the screening visit
  2. Calculated serum LDL-C \<100 mg/dL (2.59 mmol/L) and high or moderate CV risk at the screening visit
  3. A 10-year fatal cardiovascular disease risk score \<1% at the screening visit

(The inclusion/ exclusion criteria provided above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial).

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
314 participants (actual)

Study arms

  • Other
    Atorvastatin (statin rechallenge arm)

    Atorvastatin 20 mg over-encapsulated tablets orally once daily (QD) for 24 weeks and placebo (for alirocumab) subcutaneous (SC) injection every two weeks (Q2W) for 24 weeks added to stable lipid-modifying therapy (LMT).

    Drug: Atorvastatin · Drug: Placebo

  • Active comparator
    Ezetimibe

    Ezetimibe 10 mg over-encapsulated tablets orally QD for 24 weeks and placebo (for alirocumab) SC injection Q2W for 24 weeks added to stable LMT.

    Drug: Ezetimibe · Drug: Placebo

  • Experimental
    Alirocumab 75 mg/ up to 150 mg

    Alirocumab 75 mg SC injection Q2W for 24 weeks and placebo (for atorvastatin/ezetimibe) over-encapsulated tablets orally QD for 24 weeks added to stable LMT. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on cardiovascular risk.

    Drug: Alirocumab · Drug: Placebo

Interventions

  • Atorvastatin over-encapsulated tablets.

  • Ezetimibe over-encapsulated tablet.

    Also known as: Zetia

  • Alirocumab SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.

    Also known as: REGN727/SAR236553

  • DrugPlacebo

    Placebo for alirocumab, ezitimibe and atorvastatin.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--To-Treat (ITT) Analysis

    Calculated LDL-C values were obtained from Friedewald formula. Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 24

Secondary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 24 - On--Treatment Analysis

    Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).

    Time frame: From Baseline to Week 24

  2. Percent Change From Baseline in Calculated LDL--C at Week 12 -- ITT Analysis

    Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  3. Percent Change From Baseline in Calculated LDL-C at Week 12 - On--Treatment Analysis

    Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).

    Time frame: From Baseline to Week 12

  4. Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 -- ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post--baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  5. Percent Change From Baseline in Apo B at Week 24 -- On--Treatment Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first).

    Time frame: From Baseline to Week 24

  6. Percent Change From Baseline in Non--High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 -- ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  7. Percent Change From Baseline in Non--HDL-C at Week 24 -- On--Treatment Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first).

    Time frame: From Baseline to Week 24

  8. Percent Change From Baseline in Total Cholesterol (Total--C) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  9. Percent Change From Baseline in Apo B at Week 12 -- ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  10. Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  11. Percent Change From Baseline in Total-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  12. Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis

    Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).

    Time frame: Up to Week 24

  13. Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis

    Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first (on-treatment analysis).

    Time frame: Up to Week 24

  14. Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis

    Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).

    Time frame: Up to Week 24

  15. Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis

    Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first (on-treatment analysis).

    Time frame: Up to Week 24

  16. Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis

    Combined Estimate for Adjusted Mean (Standard Error) at Week 24 from multiple imputation followed by robust regression including all available post-baseline data from Week 4 to Week 24 regardless of status on or off-treatment.

    Time frame: From Baseline to Week 24

  17. Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  18. Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis

    Combined Estimate for Adjusted Mean (Standard Error) at Week 24 from multiple imputation followed by robust regression including all available post-baseline data from Week 4 to Week 24 regardless of status on or off-treatment.

    Time frame: From Baseline to Week 24

  19. Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  20. Percent Change From Baseline in Lipoprotein(a) at Week 12 -- ITT Analysis

    Combined Estimate for Adjusted Mean (Standard Error) at Week 24 from multiple imputation followed by robust regression including all available post-baseline data from Week 4 to Week 24 regardless of status on or off-treatment.

    Time frame: From Baseline to Week 12

  21. Percent Change in HDL-C From Baseline to Week 12 -- ITT Analysis

    Least-squares (LS) means and standard errors (SE) taken from MMRM (mixed-effect model with repeated measures) analysis

    Time frame: From Baseline to Week 12

  22. Percent Change in Fasting Triglycerides From Baseline to Week 12 -- ITT Analysis

    Combined Estimate for Adjusted Mean (Standard Error) at Week 24 from multiple imputation followed by robust regression including all available post-baseline data from Week 4 to Week 24 regardless of status on or off-treatment.

    Time frame: From Baseline to Week 12

  23. Percent Change From Baseline in Apo A--1 at Week 12 -- ITT Analysis

    Least squares (LS) means and standard errors (SE) taken from MMRM (mixed effect model with repeated measures) analysis.

    Time frame: From Baseline to Week 12

Other outcomes

  1. Percentage of Participants Who Experienced Skeletal Muscle-related Adverse Event (AE)

    Skeletal muscle-related adverse events were a predefined category including myalgia, muscle spasms, muscular weakness, musculoskeletal stiffness and muscle fatigue. Events that developed during treatment emergent adverse events period (the time from the first double-blindstudy treatment \[injection or capsules, whichever came first\] up to the day of the last double-blind injection + 70 days ) are reported.

    Time frame: From Baseline up to Week 24

  2. Percent Change From Baseline in Calculated LDL-C at Week 24 Versus Atorvastatin - Raw Data Description - Intent-To-Treat (ITT) Analysis

    Time frame: From Baseline up to Week 24

07

Results

Posted Aug 28, 2015

Participant flow

The study was conducted at 67 sites in 8 countries. Overall, 519 participants were screened between 28 September 2012 and 11 August 2013, 158 of whom were screen failures. Screen failures were mainly due to exclusion criteria met. After screening, 361 participants entered into a 4-week single blind placebo run-in period.

Participant flow — Overall Study
MilestoneAtorvastatin (Statin Rechallenge Arm)Ezetimibe (Active Comparator)Alirocumab 75 mg/ up to 150 mg
Started63125126
Treated63124126
Completed428296
Not completed214330
Withdrew: Randomized but not treated010
Withdrew: Adverse event163123
Withdrew: Poor compliance to protocol200
Withdrew: Other3117

Outcome measures

PrimaryPercent Change From Baseline in Calculated LDL-C at Week 24 - Intent--To-Treat (ITT) Analysis

Calculated LDL-C values were obtained from Friedewald formula. Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--To-Treat (ITT) Analysis
percent changeEzetimibeAlirocumab 75 mg/ up to 150 mg
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--To-Treat (ITT) Analysis-14.6 ± 2.2-45.0 ± 2.2
Statistical analysis
  • Ezetimibe vs Alirocumab 75 mg/ up to 150 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -30.4 · 95% CI -36.6 to -24.2
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 24 - On--Treatment Analysis

Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 - On--Treatment Analysis
percent changeEzetimibeAlirocumab 75 mg/ up to 150 mg
Percent Change From Baseline in Calculated LDL-C at Week 24 - On--Treatment Analysis-17.1 ± 2.0-52.2 ± 2.0
Statistical analysis
  • Ezetimibe vs Alirocumab 75 mg/ up to 150 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -35.1 · 95% CI -40.7 to -29.5
SecondaryPercent Change From Baseline in Calculated LDL--C at Week 12 -- ITT Analysis

Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL--C at Week 12 -- ITT Analysis
percent changeEzetimibeAlirocumab 75 mg/ up to 150 mg
Percent Change From Baseline in Calculated LDL--C at Week 12 -- ITT Analysis-15.6 ± 2.0-47.0 ± 1.9
Statistical analysis
  • Ezetimibe vs Alirocumab 75 mg/ up to 150 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -31.5 · 95% CI -36.9 to -26.1
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 - On--Treatment Analysis

Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - On--Treatment Analysis
percent changeEzetimibeAlirocumab 75 mg/ up to 150 mg
Percent Change From Baseline in Calculated LDL-C at Week 12 - On--Treatment Analysis-18.0 ± 1.8-51.2 ± 1.7
Statistical analysis
  • Ezetimibe vs Alirocumab 75 mg/ up to 150 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -33.1 · 95% CI -38.0 to -28.2
SecondaryPercent Change From Baseline in Apolipoprotein (Apo) B at Week 24 -- ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post--baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 -- ITT Analysis
percent changeEzetimibeAlirocumab 75 mg/ up to 150 mg
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 -- ITT Analysis-11.2 ± 1.7-36.3 ± 1.7
Statistical analysis
  • Ezetimibe vs Alirocumab 75 mg/ up to 150 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -25.1 · 95% CI -29.8 to -20.4
SecondaryPercent Change From Baseline in Apo B at Week 24 -- On--Treatment Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 24 -- On--Treatment Analysis
percent changeEzetimibeAlirocumab 75 mg/ up to 150 mg
Percent Change From Baseline in Apo B at Week 24 -- On--Treatment Analysis-14.4 ± 1.4-42.6 ± 1.3
Statistical analysis
  • Ezetimibe vs Alirocumab 75 mg/ up to 150 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -28.2 · 95% CI -32.1 to -24.4
SecondaryPercent Change From Baseline in Non--High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 -- ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non--High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 -- ITT Analysis
percent changeEzetimibeAlirocumab 75 mg/ up to 150 mg
Percent Change From Baseline in Non--High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 -- ITT Analysis-14.6 ± 1.7-40.2 ± 1.7
Statistical analysis
  • Ezetimibe vs Alirocumab 75 mg/ up to 150 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -25.6 · 95% CI -30.4 to -20.8
SecondaryPercent Change From Baseline in Non--HDL-C at Week 24 -- On--Treatment Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non--HDL-C at Week 24 -- On--Treatment Analysis
percent changeEzetimibeAlirocumab 75 mg/ up to 150 mg
Percent Change From Baseline in Non--HDL-C at Week 24 -- On--Treatment Analysis-17.1 ± 1.5-46.9 ± 1.4
Statistical analysis
  • Ezetimibe vs Alirocumab 75 mg/ up to 150 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -29.8 · 95% CI -33.9 to -25.8
SecondaryPercent Change From Baseline in Total Cholesterol (Total--C) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol (Total--C) at Week 24 - ITT Analysis
percent changeEzetimibeAlirocumab 75 mg/ up to 150 mg
Percent Change From Baseline in Total Cholesterol (Total--C) at Week 24 - ITT Analysis-10.9 ± 1.4-31.8 ± 1.4
Statistical analysis
  • Ezetimibe vs Alirocumab 75 mg/ up to 150 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -20.8 · 95% CI -24.7 to -17.0
SecondaryPercent Change From Baseline in Apo B at Week 12 -- ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 12 -- ITT Analysis
percent changeEzetimibeAlirocumab 75 mg/ up to 150 mg
Percent Change From Baseline in Apo B at Week 12 -- ITT Analysis-11.6 ± 1.5-36.1 ± 1.5
Statistical analysis
  • Ezetimibe vs Alirocumab 75 mg/ up to 150 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -24.5 · 95% CI -28.7 to -20.4
SecondaryPercent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
percent changeEzetimibeAlirocumab 75 mg/ up to 150 mg
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis-15.8 ± 1.5-41.5 ± 1.5
Statistical analysis
  • Ezetimibe vs Alirocumab 75 mg/ up to 150 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -25.7 · 95% CI -29.9 to -21.5
SecondaryPercent Change From Baseline in Total-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
percent changeEzetimibeAlirocumab 75/ up to 150
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis-11.6 ± 1.2-32.7 ± 1.2
Statistical analysis
  • Ezetimibe vs Alirocumab 75/ up to 150 · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -21.1 · 95% CI -24.5 to -17.7
SecondaryPercentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis

Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis
percentage of participantsEzetimibeAlirocumab 75 mg/ up to 150 mg
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis4.441.9
Statistical analysis
  • Ezetimibe vs Alirocumab 75 mg/ up to 150 mg · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.05.) · Odds ratio (or): 19.5 · 95% CI 6.9 to 55.2
SecondaryPercentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis

Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first (on-treatment analysis).

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis
percentage of participantsEzetimibeAlirocumab 75 mg/ up to 150 mg
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis5.651.2
Statistical analysis
  • Ezetimibe vs Alirocumab 75 mg/ up to 150 mg · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.05.) · Odds ratio (or): 24.9 · 95% CI 8.6 to 71.9
SecondaryPercentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis

Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
percentage of participantsEzetimibeAlirocumab 75 mg/ up to 150 mg
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis0.832.5
Statistical analysis
  • Ezetimibe vs Alirocumab 75 mg/ up to 150 mg · Regression, Exact Conditional Logistic · p = <0.0001 (Threshold for significance ≤ 0.05.) · Odds ratio (or): 71.5 · 95% CI 11.1 to 3022.1
SecondaryPercentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis

Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first (on-treatment analysis).

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis
percentage of participantsEzetimibeAlirocumab 75 mg/ up to 150 mg
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis0.839.0
Statistical analysis
  • Ezetimibe vs Alirocumab 75 mg/ up to 150 mg · Regression, Exact Conditional Logistic · p = <0.0001 (Threshold for significance ≤ 0.05.) · Odds ratio (or): 109.8 · 95% CI 16.5 to 4759.3
SecondaryPercent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis

Combined Estimate for Adjusted Mean (Standard Error) at Week 24 from multiple imputation followed by robust regression including all available post-baseline data from Week 4 to Week 24 regardless of status on or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis
percent changeEzetimibeAlirocumab 75 mg/ up to 150 mg
Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis-7.3 ± 2.5-25.9 ± 2.4
Statistical analysis
  • Ezetimibe vs Alirocumab 75 mg/ up to 150 mg · Regression, Robust · p = <0.0001 (Threshold for significance ≤ 0.05.) · Adjusted mean difference: -18.7 · 95% CI -25.5 to -11.8
SecondaryPercent Change From Baseline in HDL-C at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
percent changeEzetimibeAlirocumab 75 mg/ up to 150 mg
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis6.8 ± 1.77.7 ± 1.7
Statistical analysis
  • Ezetimibe vs Alirocumab 75 mg/ up to 150 mg · Mixed Models Analysis · p = =0.6997 (Threshold for significance ≤ 0.05.) · Ls mean difference: 0.9 · 95% CI -3.8 to 5.6
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis

Combined Estimate for Adjusted Mean (Standard Error) at Week 24 from multiple imputation followed by robust regression including all available post-baseline data from Week 4 to Week 24 regardless of status on or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
percent changeEzetimibeAlirocumab 75 mg/ up to 150 mg
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis-3.6 ± 2.8-9.3 ± 2.7
SecondaryPercent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis
percent changeEzetimibeAlirocumab 75 mg/ up to 150 mg
Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis2.9 ± 1.24.8 ± 1.2
SecondaryPercent Change From Baseline in Lipoprotein(a) at Week 12 -- ITT Analysis

Combined Estimate for Adjusted Mean (Standard Error) at Week 24 from multiple imputation followed by robust regression including all available post-baseline data from Week 4 to Week 24 regardless of status on or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein(a) at Week 12 -- ITT Analysis
percent changeEzetimibeAlirocumab 75 mg/ up to 150 mg
Percent Change From Baseline in Lipoprotein(a) at Week 12 -- ITT Analysis-4.5 ± 2.3-21.7 ± 2.2
SecondaryPercent Change in HDL-C From Baseline to Week 12 -- ITT Analysis

Least-squares (LS) means and standard errors (SE) taken from MMRM (mixed-effect model with repeated measures) analysis

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change in HDL-C From Baseline to Week 12 -- ITT Analysis
percent changeEzetimibeAlirocumab 75 mg/ up to 150 mg
Percent Change in HDL-C From Baseline to Week 12 -- ITT Analysis7.6 ± 1.29.0 ± 1.2
SecondaryPercent Change in Fasting Triglycerides From Baseline to Week 12 -- ITT Analysis

Combined Estimate for Adjusted Mean (Standard Error) at Week 24 from multiple imputation followed by robust regression including all available post-baseline data from Week 4 to Week 24 regardless of status on or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Mean · percent change
Percent Change in Fasting Triglycerides From Baseline to Week 12 -- ITT Analysis
percent changeEzetimibeAlirocumab 75 mg/ up to 150 mg
Percent Change in Fasting Triglycerides From Baseline to Week 12 -- ITT Analysis-9.4 ± 2.6-8.0 ± 2.5
SecondaryPercent Change From Baseline in Apo A--1 at Week 12 -- ITT Analysis

Least squares (LS) means and standard errors (SE) taken from MMRM (mixed effect model with repeated measures) analysis.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo A--1 at Week 12 -- ITT Analysis
percent changeEzetimibeAlirocumab 75 mg/ up to 150 mg
Percent Change From Baseline in Apo A--1 at Week 12 -- ITT Analysis3.9 ± 1.05.5 ± 1.0
Other pre-specifiedPercentage of Participants Who Experienced Skeletal Muscle-related Adverse Event (AE)

Skeletal muscle-related adverse events were a predefined category including myalgia, muscle spasms, muscular weakness, musculoskeletal stiffness and muscle fatigue. Events that developed during treatment emergent adverse events period (the time from the first double-blindstudy treatment \[injection or capsules, whichever came first\] up to the day of the last double-blind injection + 70 days ) are reported.

Time frame:
From Baseline up to Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experienced Skeletal Muscle-related Adverse Event (AE)
Percentage of ParticipantsAtorvastatin (Statin Rechallenge Arm)Ezetimibe (Active Comparator)Alirocumab 75 mg/ up to 150 mg
Any skeletal muscle-related AE46.041.132.5
Leading to treatment discontinuation22.220.215.9
Other pre-specifiedPercent Change From Baseline in Calculated LDL-C at Week 24 Versus Atorvastatin - Raw Data Description - Intent-To-Treat (ITT) Analysis
Time frame:
From Baseline up to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 Versus Atorvastatin - Raw Data Description - Intent-To-Treat (ITT) Analysis
percent changeAtorvastatin (Statin Rechallenge Arm)Ezetimibe (Active Comparator)Alirocumab 75 mg/ up to 150 mg
Percent Change From Baseline in Calculated LDL-C at Week 24 Versus Atorvastatin - Raw Data Description - Intent-To-Treat (ITT) Analysis-31.9 ± 25.1-15.2 ± 22.4-47.3 ± 22.7

Adverse events

Collected over From Baseline up to the Last Double-Blind Injection Date + 70 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atorvastatin—7/63 (11.1%)35/63 (55.6%)
Ezetimibe—10/124 (8.1%)63/124 (50.8%)
Alirocumab 75 mg/ up to 150 mg—12/126 (9.5%)57/126 (45.2%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventAtorvastatinEzetimibeAlirocumab 75 mg/ up to 150 mg
Non-Cardiac chest painGeneral disorders1/634/1240/126
Angina unstableCardiac disorders1/630/1241/126
NauseaGastrointestinal disorders1/630/1240/126
Small intestinal obstructionGastrointestinal disorders1/630/1240/126
VomitingGastrointestinal disorders1/630/1240/126
OsteoarthritisMusculoskeletal and connective tissue disorders1/630/1240/126
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/630/1240/126
Ovarian epithelial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/630/1240/126
Transient ischaemic attackNervous system disorders1/630/1240/126
Aortic aneurysmVascular disorders1/630/1240/126
Most frequent other events
Most frequent other events
EventAtorvastatinEzetimibeAlirocumab 75 mg/ up to 150 mg
MyalgiaMusculoskeletal and connective tissue disorders17/6329/12431/126
Muscle spasmsMusculoskeletal and connective tissue disorders7/639/1245/126
NasopharyngitisInfections and infestations2/6310/1248/126
FatigueGeneral disorders5/634/1246/126
ArthralgiaMusculoskeletal and connective tissue disorders5/639/1246/126
Back painMusculoskeletal and connective tissue disorders5/637/1245/126
Muscular weaknessMusculoskeletal and connective tissue disorders4/632/1241/126
HeadacheNervous system disorders4/636/1246/126
ParaesthesiaNervous system disorders4/630/1244/126
Upper respiratory tract infectionInfections and infestations2/635/1247/126

Baseline characteristics

Age, Continuous
Age, Continuous(years)Atorvastatin (Statin Rechallenge Arm)Ezetimibe (Active Comparator)Alirocumab 75 mg/ up to 150 mgTotal
Mean63.4 ± 9.562.8 ± 10.164.1 ± 9.063.4 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Atorvastatin (Statin Rechallenge Arm)Ezetimibe (Active Comparator)Alirocumab 75 mg/ up to 150 mgTotal
Female285856142
Male356770172
Low Density Lipoprotein Cholesterol (LDL-C) in mg/dL
Low Density Lipoprotein Cholesterol (LDL-C) in mg/dL(mg/dL)Atorvastatin (Statin Rechallenge Arm)Ezetimibe (Active Comparator)Alirocumab 75 mg/ up to 150 mgTotal
Mean187.3 ± 59.5193.5 ± 70.9191.1 ± 72.7191.3 ± 69.3
LDL-C in mmol/L
LDL-C in mmol/L(mmol/L)Atorvastatin (Statin Rechallenge Arm)Ezetimibe (Active Comparator)Alirocumab 75 mg/ up to 150 mgTotal
Mean4.85 ± 1.545.011 ± 1.8374.951 ± 1.8834.954 ± 1.796
08

Study locations

70 sites
  • Anaheim, California, United States
  • Beverly Hills, California, United States
  • Mission Viejo, California, United States
  • Newport Beach, California, United States
  • Northridge, California, United States
  • Thousand Oaks, California, United States
  • Hartford, Connecticut, United States
  • Boynton Beach, Florida, United States
  • Jacksonville, Florida, United States
  • Lakeland, Florida, United States
  • Pembroke Pines, Florida, United States
  • Sarasota, Florida, United States
  • Tampa, Florida, United States
  • Trinity, Florida, United States
  • Addison, Illinois, United States
  • Chicago, Illinois, United States
  • Indianapolis, Indiana, United States
  • Kansas City, Kansas, United States
  • Auburn, Maine, United States
  • Boston, Massachusetts, United States
  • Minneapolis, Minnesota, United States
  • Rochester, Minnesota, United States
  • Saint Louis, Missouri, United States
  • Clifton, New Jersey, United States
  • New York, New York, United States
  • Poughkeepsie, New York, United States
  • Durham, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Marion, Ohio, United States
  • Danville, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Port Matilda, Pennsylvania, United States
  • Scranton, Pennsylvania, United States
  • Wilkes-Barre, Pennsylvania, United States
  • Summerville, South Carolina, United States
  • Kingsport, Tennessee, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • Fort Worth, Texas, United States
  • Salt Lake City, Utah, United States
  • Richmond, Virginia, United States
  • Feldkirch, Austria
  • Graz, Austria
  • Innsbruck, Austria
  • Chicoutimi, Quebec, Canada
  • Montreal (2 locations), Quebec, Canada
  • Sainte-Foy, Quebec, Canada
  • Bron, France
  • Dijon, France
  • Lille, France
  • Paris, France
  • Saint-Herblain, France
  • Venissieux, France
  • Holon, Israel
  • Jerusalem, Israel
  • Ofakim, Israel
  • Safed, Israel
  • Tel-Hashomer, Israel
  • Cinisello Balsamo, Italy
  • Napoli, Italy
  • Palermo, Italy
  • Roma, Italy
  • Oslo (2 Locations), Norway
  • Burton-on-Trent, United Kingdom
  • Chesterfield, United Kingdom
  • Isle Of White, United Kingdom
  • Londonderry/N. Ireland, United Kingdom
  • Peterborough, United Kingdom
  • Salford, United Kingdom
  • Stevenage, United Kingdom
09

References and documents

Publications

  • Moriarty PM, Jacobson TA, Bruckert E, Thompson PD, Guyton JR, Baccara-Dinet MT, Gipe D. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol. 2014 Nov-Dec;8(6):554-561. doi: 10.1016/j.jacl.2014.09.007. Epub 2014 Sep 19. PubMed 25499937 ↗
  • Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Kopecky SL, Baccara-Dinet MT, Du Y, Pordy R, Gipe DA; ODYSSEY ALTERNATIVE Investigators. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015 Nov-Dec;9(6):758-769. doi: 10.1016/j.jacl.2015.08.006. Epub 2015 Aug 29. PubMed 26687696 ↗
  • Mahmood T, Minnier J, Ito MK, Li QH, Koren A, Kam IW, Fazio S, Shapiro MD. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. Eur J Prev Cardiol. 2021 Jul 23;28(8):816-822. doi: 10.1177/2047487320915803. Epub 2020 Apr 10. PubMed 34298554 ↗
  • Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Baccara-Dinet MT, Zhao J, Donahue S, Ali S, Manvelian G, Pordy R. Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial. J Clin Lipidol. 2020 Jan-Feb;14(1):88-97.e2. doi: 10.1016/j.jacl.2020.01.001. Epub 2020 Jan 13. PubMed 32192644 ↗
  • Leiter LA, Tinahones FJ, Karalis DG, Bujas-Bobanovic M, Letierce A, Mandel J, Samuel R, Jones PH. Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Diabet Med. 2018 Dec;35(12):1742-1751. doi: 10.1111/dme.13817. Epub 2018 Oct 9. PubMed 30183102 ↗
  • Defesche JC, Stefanutti C, Langslet G, Hopkins PN, Seiz W, Baccara-Dinet MT, Hamon SC, Banerjee P, Kastelein JJP. Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. J Clin Lipidol. 2017 Nov-Dec;11(6):1338-1346.e7. doi: 10.1016/j.jacl.2017.08.016. Epub 2017 Sep 4. Erratum In: J Clin Lipidol. 2020 Sep - Oct;14(5):742. doi: 10.1016/j.jacl.2020.09.010. PubMed 28964736 ↗
  • Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac L, Minini P, Eckel RH, Cannon CP. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016 Dec 13;134(24):1931-1943. doi: 10.1161/CIRCULATIONAHA.116.024604. Epub 2016 Oct 24. PubMed 27777279 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2012 to primary completion in May 2014, 20 months.

Results were first posted in Aug 2015, 1 year 2 months after primary completion. A results delay was requested in Jan 2015.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 20 months is above that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2012
First posted
Oct 18, 2012
StartActual
Sep 30, 2012
Primary completionActual
May 31, 2014
CompletionActual
May 31, 2017
Results delay requested
Jan 24, 2015
Results first posted
Aug 28, 2015
Last update
Jun 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01709513
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Oct 18, 2012
Start date
Sep 30, 2012
Primary completion
May 31, 2014
Completion
May 31, 2017
Results posted
Aug 28, 2015
Last update
Jun 23, 2020

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion